Linked Life Data

17323037

Source:http://linkedlifedata.com/resource/pubmed/id/17323037

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
1
pubmed:dateCreated
2007-2-26
pubmed:abstractText
Captopril was the first oral angiotensin-converting enzyme (ACE) inhibitor available and, as such, has been extensively studied and in clinical use for many years. Several studies have defined captopril's efficacy in the treatment of congestive heart failure (CHF) as well as determined its safety profile. The most common adverse hematologic reactions associated with captopril use include neutropenia and agranulocytosis. This paper describes an uncommon and a potentially serious hematologic side effect associated with captopril-hemolytic anemia.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Feb
pubmed:issn
0340-9937
pubmed:author
pubmed:issnType
Print
pubmed:volume
32
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
62-4
pubmed:meshHeading
pubmed:year
2007
pubmed:articleTitle
Hemolytic anemia: a rare but potentially serious adverse effect of captopril.
pubmed:affiliation
Duke University Medical Center, Durham, NC, USA.
pubmed:publicationType
Journal Article, Case Reports